New drug combo targets hard-to-treat HER2 cancers
NCT ID NCT03448042
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 20 times
Summary
This early-stage trial tests a new drug called runimotamab, given alone or with trastuzumab, in people with advanced HER2-expressing cancers. The main goal is to check safety and how the drug moves through the body. About 123 adults with solid tumors that have spread or cannot be removed are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda
Milan, Lombardy, 20162, Italy
-
Asan Medical Center
Seoul, 05505, South Korea
-
Centre Léon Bérard
Lyon, Rhône, 69008, France
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Churchill Hospital
Oxford, Oxfordshire, OX3 7LJ, United Kingdom
-
EDOG - Institut Bergonie - PPDS
Bordeaux, Gironde, 33000, France
-
Grand Hopital de Charleroi asbl
Charleroi, 6000, Belgium
-
Gustave Roussy
Villejuif, Val-de-Marne, 94805, France
-
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, 1066 CX, Netherlands
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
-
Institut Claudius Regaud
Toulouse, 31059, France
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10017, United States
-
National Cancer Center East
Chiba, 277-8577, Japan
-
National Cancer Centre
Singapore, 168583, Singapore
-
National Taiwan University Hospital
Taipei, 10048, Taiwan
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Rigshospitalet-Blegdamsvej 9
Copenhagen, 2100, Denmark
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START MADRID_Hospital Universiario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
START MADRID_Hospital Universitario HM Sanchinarro - CIOCC - EDOS
Madrid, 28050, Spain
-
Seoul National University Hospital
Seoul, 110-744, South Korea
-
Washington University
Saint Louis, Michigan, 63130, United States
-
Yale University
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.